Skip to content

Study · Animal study (in vivo) · rat · 1997

5 results

Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats.

Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, Turkovic B, Rotkvic I, Mise S, Zoricic I, Konjevoda P, Perovic D and 11 more

Show all authors

Simicevic V, Separovic J, Hanzevacki M, Ljubanovic D, Artukovic B, Bratulic M, Tisljar M, Rekic B, Gjurasin M, Miklic P, Buljat G

Journal of physiology, Paris1 May 1997Cited by 42 (Europe PMC)

PMID9403784 (opens in a new tab)DOI10.1016/s0928-4257(97)89474-0 (opens in a new tab)PepBankPUB-09403784
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given NSAIAs, BPC‑157 reduced the prominent stomach lesions seen in control rats.

    In plain wordsIn rats given anti-inflammatory painkillers, BPC‑157 reduced stomach lesions compared with controls.

    Peptide
    BPC-157
    Outcome
    DecreaseNSAID-induced stomach lesions
    Study

    ratn: not reported in source

    indomethacin, aspirin and diclofenac gastrointestinal lesions
    Comparator
    Control
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg or 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Given with the investigated NSAIAs, BPC 157 consistently reduced the otherwise prominent lesions in the stomach of the control rats
    2 context sentences
    Summary · context
    In gastrointestinal lesions (indomethacin (30 mg/kg s.c.), aspirin (400 mg/kg i.g.) and diclofenac (125 mg/kg i.p.) studies, BPC 157 (10 micrograms or 10 ng/kg i.p.) was regularly given simultaneously and/or 1 h prior to drug application (indomethacin).
    Summary · context
    Consequently, its effect on chronic inflammation lesions, such as adjuvant arthritis, and non-steroidal anti-inflammatory agents (NSAIAs)-induced gastrointestinal lesions was simultaneously studied in rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given indomethacin, BPC‑157 reduced lesions in the small intestine.

    In plain wordsIn rats given indomethacin, BPC‑157 reduced small intestine lesions.

    Peptide
    BPC-157
    Outcome
    DecreaseIndomethacin-induced small intestine lesions
    Study

    ratn: not reported in source

    indomethacin gastrointestinal lesions
    Comparator
    Control
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg or 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    as well as the lesions in the small intestine in the indomethacin groups.
    2 context sentences
    Summary · context
    In gastrointestinal lesions (indomethacin (30 mg/kg s.c.), aspirin (400 mg/kg i.g.) and diclofenac (125 mg/kg i.p.) studies, BPC 157 (10 micrograms or 10 ng/kg i.p.) was regularly given simultaneously and/or 1 h prior to drug application (indomethacin).
    Summary · context
    Consequently, its effect on chronic inflammation lesions, such as adjuvant arthritis, and non-steroidal anti-inflammatory agents (NSAIAs)-induced gastrointestinal lesions was simultaneously studied in rats.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with adjuvant arthritis, a single BPC‑157 application considerably reduced lesion development.

    In plain wordsIn rats with induced arthritis, one dose of BPC‑157 considerably reduced lesion development.

    Peptide
    BPC-157
    Outcome
    DecreaseAdjuvant arthritis lesion development, single dose
    Study

    ratn: not reported in source

    Freund's adjuvant arthritis
    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 µg or 10 ng/kg · intraperitoneal · single applicationAs given in this study (rat).

    Source sentences

    Summary
    In the adjuvant arthritis studies, the lesion's development seems to be considerably reduced after single pentadecapeptide medication
    2 context sentences
    Summary · context
    In the adjuvant arthritis (tail-application of 0.2 mL of Freund's adjuvant) studies (14 days, 30 days, 1 year) BPC 157 (10 micrograms or 10 ng/kg i.p.), it was given as a single application (at 1 h either before or following the application of Freund's adjuvant) or in a once daily regimen (0-14th da…
    Summary · context
    Consequently, its effect on chronic inflammation lesions, such as adjuvant arthritis, and non-steroidal anti-inflammatory agents (NSAIAs)-induced gastrointestinal lesions was simultaneously studied in rats.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with adjuvant arthritis, daily BPC‑157 attenuated lesion development even more than a single application.

    In plain wordsIn rats with induced arthritis, daily BPC‑157 reduced lesions even more than one dose.

    Peptide
    BPC-157
    Outcome
    DecreaseAdjuvant arthritis lesion development, daily dosing
    Study

    ratn: not reported in source

    Freund's adjuvant arthritis
    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 µg or 10 ng/kg · intraperitoneal · once dailyAs given in this study (rat).

    Source sentences

    Summary
    and even more attenuated in rats daily treated with BPC 157.
    2 context sentences
    Summary · context
    In the adjuvant arthritis (tail-application of 0.2 mL of Freund's adjuvant) studies (14 days, 30 days, 1 year) BPC 157 (10 micrograms or 10 ng/kg i.p.), it was given as a single application (at 1 h either before or following the application of Freund's adjuvant) or in a once daily regimen (0-14th da…
    Summary · context
    Consequently, its effect on chronic inflammation lesions, such as adjuvant arthritis, and non-steroidal anti-inflammatory agents (NSAIAs)-induced gastrointestinal lesions was simultaneously studied in rats.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with already established adjuvant arthritis, BPC‑157 had a salutary effect after 2 weeks that was also seen after 1 year of application.

    In plain wordsIn rats with existing induced arthritis, BPC‑157 helped after 2 weeks and the effect was still seen after 1 year.

    Peptide
    BPC-157
    Outcome
    DecreaseEstablished adjuvant arthritis
    Study

    ratn: not reported in source

    established Freund's adjuvant arthritis
    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 µg or 10 ng/kg · intraperitoneal · 2 weeks to 1 yearAs given in this study (rat).

    Source sentences

    Summary
    As a therapy of already established adjuvant arthritis, its salutary effect consistently appeared already after 2 weeks of medication and it could be clearly seen also after 1 year of application.
    2 context sentences
    Summary · context
    In the adjuvant arthritis (tail-application of 0.2 mL of Freund's adjuvant) studies (14 days, 30 days, 1 year) BPC 157 (10 micrograms or 10 ng/kg i.p.), it was given as a single application (at 1 h either before or following the application of Freund's adjuvant) or in a once daily regimen (0-14th da…
    Summary · context
    Consequently, its effect on chronic inflammation lesions, such as adjuvant arthritis, and non-steroidal anti-inflammatory agents (NSAIAs)-induced gastrointestinal lesions was simultaneously studied in rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.